Breaking Finance News

Zacks Investment Research downgraded Cancer Genetics Inc (NASDAQ:CGIX) to Hold in a statement released earlier today.

Zacks Investment Research has downgraded Cancer Genetics Inc (NASDAQ:CGIX) to Hold in a report released on 11/28/2016.

On Tuesday November 15, 2016, Zacks Investment Research released a statement on Cancer Genetics Inc (NASDAQ:CGIX) upped the target price from $0.00 to $1.75. At the time, this indicated a possible upside of 0.09%.

Boasting a price of $1.55, Cancer Genetics Inc (NASDAQ:CGIX) traded -3.13% lower on the day. With the last stock price close down -19.59% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Cancer Genetics Inc has recorded a 50-day average of $1.53 and a two hundred day average of $1.93. Volume of trade was up over the average, with 303,266 shares of CGIX changing hands over the typical 117,481

See Chart Below

Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics Inc has a 52 week low of $1.10 and a 52 week high of $3.82 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 firms have reported on the stock. The consensus target price is $8.42 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.